Home   /  Find a Trial  /  See All TrialsHELP /  AYUDA /  求助 : (415) 476-5777 | Click to print page Print
 

See All Trials

QuickViews

Match by Tumor Type:

Newly Diagnosed (Stage I-III)
Biomarker status:
 Hormone-positive (ER+ and/or PR+)
 HER2-positive (HER2+)
 Triple negative (ER-/PR-/HER2-)
Inflammatory Breast Cancer
Biomarker status:
 Hormone-positive (ER+ and/or PR+)
 HER2-positive (HER2+)
 Triple negative (ER-/PR-/HER2-)

View by Trial Type:

Treatment:

 

Non-Treatment:

see All Trials

Sort by zip code:  

 

Share

Facebook
Twitter
Twitter

 
Having Children

Sexual and Reproductive Health Study

Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma (NCT01788839)

Summary

Cancer and its treatment may affect sexual and reproductive health. To help researchers learn more about the problems women face, participants in this study will complete questionnaires on sexuality and pregnancy before, during, and after cancer treatment. The information will be used to help doctors identify which women are most likely to have early menopause or develop sexual problems during cancer therapy, or have difficulty getting pregnant after cancer treatment. To be eligible for this study a woman must be age 50 or younger, newly diagnosed with breast cancer, and planning on having, or within one month of starting, chemotherapy.

What's Involved    Contact information

Evaluating the Effects of Chemotherapy on Ovarian Function

Multi-Center Study of Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer and Lymphoma (NCT00823654)

Summary

Breast cancer treatments can affect the ovaries, making it difficult for a woman to later conceive a child. They can also bring on early menopause. Ovarian functioning can be assessed by evaluating the blood levels of certain hormones the ovaries produce. The purpose of this study is to see how different cancer treatments affect the ovaries, and whether there are ways to predict which women will be more likely to go into early menopause. Women planning to have treatment with chemotherapy (CMF or ACT) or hormone therapy (tamoxifen) are eligible for this study. Women without cancer who are being treated at the NY Medical College/Center for Human Reproduction are also eligible.

What's Involved    Contact information

Ovarian Function After DCIS and Breast Cancer

Predictors of Ovarian Insufficiency Through Serial Exams in Young Breast Cancer Patients (POISE Study) (NCT01197456)

Summary

Premenopausal women may face issues related to having children as they undergo breast cancer care, and these concerns may influence their treatment choices. Tools that can accurately predict how treatment may affect ovarian function could help women and their doctors make choices that take into account the potential impact on fertility. The goal of this study is to identify pre-chemotherapy hormonal, genetic, and ovarian imaging markers that can predict whether a woman's ovaries are likely to continue to function at the end of her cancer treatments. Participants will be followed from the time of diagnosis to five years after treatment.

What's Involved    Contact information

Improving Fertility Preservation

A Randomized Open Label Clinical Trial of Fixed Dose Letrozole vs. Titrated Letrozole for In Vitro Fertilization With Cryopreservation of Oocytes and Embryos in Breast Cancer Patients (NCT01035099)

Summary

Some breast cancer treatments may affect a woman's ability to become pregnant. Women can choose to undergo in vitro fertilization (IVF) prior to chemotherapy or radiation so that they can store their eggs and try to become pregnant at a later date. IVF involves ovarian stimulation and egg retrieval. Conventional ovarian stimulation often results in very high estrogen levels, which may be unsafe for breast cancer patients. Letrozole (Femara®) is an aromatase inhibitor used to treat hormone-sensitive tumors in postmenopausal women. It can reduce estrogen levels during IVF while still allowing for effective ovarian stimulation. This trial will compare the effectiveness of two different ways of administering letrozole during ovarian stimulation in patients who are scheduled to undergo IVF for fertility preservation due to breast cancer.

What's Involved    Contact information